Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 3
2010 2
2011 4
2012 3
2013 9
2014 4
2015 7
2016 9
2017 5
2018 3
2019 3
2020 8
2021 5
2022 6
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 2
The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).
Chen CL, Ikram K, Anqi Q, Yin WT, Chen A, Venketasubramanian N; NEURITE Investigators. Chen CL, et al. Cerebrovasc Dis. 2013;35 Suppl 1:23-9. doi: 10.1159/000346234. Epub 2013 Mar 14. Cerebrovasc Dis. 2013. PMID: 23548916 Free article.
NeuroAiD may improve cerebral blood flow and functional recovery after stroke in patients. OBJECTIVE: To investigate the effects and tolerability of NeuroAiD II in patients with VCIND. METHODS: The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study ( …
NeuroAiD may improve cerebral blood flow and functional recovery after stroke in patients. OBJECTIVE: To investigate the effects and …
A possible neuroprotective property of ethanol and/or NeuroAiD on the modulation of cognitive function.
Nasehi M, Zadeh-Tehrani SN, Khakpai F, Zarrindast MR. Nasehi M, et al. Neurotoxicol Teratol. 2020 Nov-Dec;82:106927. doi: 10.1016/j.ntt.2020.106927. Epub 2020 Aug 27. Neurotoxicol Teratol. 2020. PMID: 32861843
The aim of the current study was to assess the hypothesis that ethanol exposure would induce neurobehavioral defects which may be reversed by the neuroprotective property of NeuroAid. Adult male Wistar rats were treated with saline, ethanol (0.2 g/kg), NeuroAid (0.8 …
The aim of the current study was to assess the hypothesis that ethanol exposure would induce neurobehavioral defects which may be reversed b …
Neuroaid in stroke recovery.
Siow CH. Siow CH. Eur Neurol. 2008;60(5):264-6. doi: 10.1159/000155220. Epub 2008 Sep 9. Eur Neurol. 2008. PMID: 18781074 Free article. No abstract available.
INCOG 2.0 Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed.
Ponsford J, Velikonja D, Janzen S, Harnett A, McIntyre A, Wiseman-Hakes C, Togher L, Teasell R, Kua A, Patsakos E, Welch-West P, Bayley MT. Ponsford J, et al. J Head Trauma Rehabil. 2023 Jan-Feb 01;38(1):38-51. doi: 10.1097/HTR.0000000000000839. J Head Trauma Rehabil. 2023. PMID: 36594858
Amantadine may facilitate arousal in comatose or vegetative patients but does not enhance performance on attentional measures over the longer term. The antioxidant Chinese herbal supplement MLC901 (NeuroAiD IITM) may enhance selective attention in individuals with mild-mod …
Amantadine may facilitate arousal in comatose or vegetative patients but does not enhance performance on attentional measures over the longe …
MLC901 (NeuroAiD II) for cognition after traumatic brain injury: a pilot randomized clinical trial.
Theadom A, Barker-Collo S, Jones KM, Parmar P, Bhattacharjee R, Feigin VL. Theadom A, et al. Eur J Neurol. 2018 Aug;25(8):1055-e82. doi: 10.1111/ene.13653. Epub 2018 Apr 27. Eur J Neurol. 2018. PMID: 29611892 Free PMC article. Clinical Trial.
We conducted a 9-month pilot, randomized placebo-controlled clinical trial to examine the safety and potential effects of the herbal supplement MLC901 (NeuroAiD II) on cognitive functioning following TBI. METHODS: Adults aged 18-65 years at 1-12 months after mild or modera …
We conducted a 9-month pilot, randomized placebo-controlled clinical trial to examine the safety and potential effects of the herbal supplem …
NeuroAiD (MLC601) and amyloid precursor protein processing.
Lim YA, Murray LA, Lai MK, Chen C. Lim YA, et al. Cerebrovasc Dis. 2013;35 Suppl 1:30-7. doi: 10.1159/000346236. Epub 2013 Mar 14. Cerebrovasc Dis. 2013. PMID: 23548917 Free article.
Similarly, stroke patients have a higher level of Abeta around the area of infarct, suggesting that Abeta may mediate at least some of the secondary neurotoxicity observed in stroke patients. METHODS: To investigate the effects of MLC601 (NeuroAiD()) on regulation of APP p …
Similarly, stroke patients have a higher level of Abeta around the area of infarct, suggesting that Abeta may mediate at least some of the s …
Safety and Use of MLC601/MLC901 (NeuroAiD(TM)) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry.
Kumar R, Abu Bakar A, Thanabalan J, Paramasvaran S, Toh CJ, Jaffar A, Fadzil F, Kamalanathan P, Soon BH, Venketasubramanian N. Kumar R, et al. Brain Sci. 2020 Jul 30;10(8):499. doi: 10.3390/brainsci10080499. Brain Sci. 2020. PMID: 32751570 Free PMC article.
Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH). The NeuroAiD Safe Treatment (NeST) Registry explores NeuroAiD use in the real-world setting. ...METHODS: The online NeST Registry of subjects with ICH given NeuroAiD pros …
Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH). The NeuroAiD Safe Treatment (NeST) Registry …
A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8-year Follow-up Study.
Pakdaman H, Amini Harandi A, Gharagozli K, Siavoshi F, Shirzadeh Barough S, Sharifipour E, Esfandani A, Ilkhani S, Tabatabaei FS, Sobhanian SA. Pakdaman H, et al. Curr Aging Sci. 2023;16(3):234-239. doi: 10.2174/1874609816666230224111759. Curr Aging Sci. 2023. PMID: 36843256 Clinical Trial.
CONCLUSION: For more than eight years, we studied monotherapy with NeuroAid (MLC601, MLC901) in patients with AD. The study contributes further to the long-term safety and efficacy data of MLC in patients with AD....
CONCLUSION: For more than eight years, we studied monotherapy with NeuroAid (MLC601, MLC901) in patients with AD. The study contribut …
74 results

Searches related to "neuroaid"